Incretin Atlas › Trials › VISTA (NCT06579092)
VISTA (NCT06579092)
AZD5004 (ECC5004) · obesity
Design
- Molecule(s)
- AZD5004 (ECC5004)
- Population
- obesity
- Phase
- 2
- Participants
- 310
- Duration
- 36 weeks
- Registry
- NCT06579092
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 mg QD | obesity | 36 | 310 | −2.7 % vs −0.6 % Δ −2.1 pp | — | — | — | — | — | — | — | — | press release |
| 15 mg QD | obesity | 36 | 310 | −6.5 % vs −0.6 % Δ −5.9 pp | — | — | — | — | — | — | — | — | press release |
| 50 mg QD (escalated every 4 weeks) | obesity | 36 | 310 | −9.2 % vs −0.6 % Δ −8.6 pp | — | — | — | — | — | — | — | — | press release |
| 75 mg QD (escalated weekly) | obesity | 36 | 310 | −11.8 % vs −0.6 % Δ −11.2 pp | — | — | — | — | — | — | — | — | press release |
| 75 mg QD (escalated every 2 weeks) | obesity | 36 | 310 | −11.1 % vs −0.6 % Δ −10.5 pp | — | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (5)
- 5 mg QD · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 15 mg QD · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 50 mg QD (escalated every 4 weeks) · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 75 mg QD (escalated weekly) · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
- 75 mg QD (escalated every 2 weeks) · weight_eff · press release
Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: VISTA (NCT06579092). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/vista/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.